SAB Biotherapeutics Provides Company Update for Full Year 2022

April 2, 2023

https://www.globenewswire.com/news-release/2023/03/31/2639063/0/en/SAB-Biotherapeutics-Provides-Company-Update-for-Full-Year-2022.html

SIOUX FALLS, S.D., March 31, 2023 (GLOBE NEWSWIRE) — SAB Biotherapeutics (Nasdaq:SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human immunoglobulin (hIgG) antibodies, also known as fully-human polyclonal antibodies, without the need for human donors, today reported financial results for the full year ended December 31, 2022, and provided a company update.

Read more at globenewswire.com

Related news for (SABS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.